Becton, Dickinson and Company (BDX)

Market Cap	48.11B
Revenue (ttm)	20.87B
Net Income (ttm)	1.50B
Shares Out	286.61M
EPS (ttm)	5.16
PE Ratio	32.51
Forward PE	11.75
Dividend	$4.16 (2.48%)
Ex-Dividend Date	Jun 9, 2025

Volume	2,621,454
Open	168.00
Previous Close	168.78
Day's Range	165.72 - 170.00
52-Week Range	166.12 - 251.99
Beta	0.34
Analysts	Buy
Price Target	254.14 (+51.41%)
Earnings Date	May 1, 2025

About BDX

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Apr 23, 1962
• Employees: 73,000
• Stock Exchange: NYSE
• Ticker Symbol: BDX
• Website: https://www.bd.com

Financial Performance

In 2024, BDX's revenue was $20.18 billion, an increase of 4.16% compared to the previous year's $19.37 billion. Earnings were $1.71 billion, an increase of 19.73%.

Analyst Forecast

According to 8 analysts, the average rating for BDX stock is "Buy." The 12-month stock price forecast is $254.14, which is an increase of 51.41% from the latest price.

Price Target

$254.14

(51.41% upside)

Analyst Consensus: Buy